Temporal dynamics of ferroptosis markers and neuroprotective intervention in cerebral ischemia-reperfusion injury: Insights for therapeutic strategy development

Articles in Press

Document Type : Original Article

Authors

1 Yunnan Provincial Key Laboratory of Entomological Biopharmaceutical R&D, College of Pharmacy, Dali University, Dali, Yunnan, PR China

2 National-Local Joint Engineering Research Center of Entomoceutics, Dali, PR China

10.22038/ijbms.2025.82625.17865

Abstract

Objective(s): This study examines the temporal dynamics of ferroptosis following cerebral ischemia-reperfusion injury (CIRI) to establish a theoretical framework for innovative therapies that enhance neuronal survival by mitigating ferroptosis.
Materials and Methods: An experimental CIRI model was established in mice via middle cerebral artery occlusion and reperfusion (MCAO/R). Behavioral assessments were conducted, and blood-brain barrier (BBB) integrity was evaluated using transmission electron microscopy. Immunoblotting and ELISA were performed to determine ferroptosis dynamics post-MCAO/R. Additionally, CIRI mice received intraperitoneal injections of Ferrostain-1 (10 mg/kg/d) and Erastin (30 mg/kg/d). The effects of ferroptosis on CIRI were further verified through 2,3,5-Triphenyltetrazolium chloride and hematoxylin-eosin staining.
Results: MCAO/R induced BBB disruption, and was associated with a reduction in GSH activity (at 1, 3, and 5 days), elevated Fe(2+) levels (at 1 day), as well as decreased MDA levels (at 3 days). Concurrently, ferroptosis markers, including NRF2, xCT, and GPX4, were significantly down-regulated on day 1, reaching their nadir by day 3, whereas HO-1 exhibited an inverse trend. Notably, Ferrostatin-1 pretreatment conferred a protective effect against CIRI, in contrast to the MCAO and Erastin groups.
Conclusion: This study elucidates the temporal dynamics of ferroptosis markers in the early stages of stroke, highlighting a therapeutic window for ferroptosis-related CIRI. These findings underscore the importance of targeting ferroptosis to improve neuronal survival and inform future CIRI therapies.

Keywords

Main Subjects

References

1. Martins SO, Mont’Alverne F, Rebello LC, Abud DG, Silva GS, Lima FO, et al. Thrombectomy for stroke in the public health care system of Brazil. N Engl J Med 2020; 382: 2316-2326.
2. Thayabaranathan T, Kim J, Cadilhac DA, Thrift AG, Donnan GA, Howard G, et al. Global stroke statistics. Int J Stroke 2022; 17: 946-956.
3. Grysiewicz RA, Thomas K, Pandey DK. Epidemiology of ischemic and hemorrhagic stroke: Incidence, prevalence, mortality, and risk factors. Neurol Clin 2008; 26: 871-895.
4. Barthels D, Das H. Current advances in ischemic stroke research and therapies. Biochim Biophys Acta Mol Basis Dis 2020; 1866: 165260-165286.
5. Sommer CJ. Ischemic stroke: Experimental models and reality. Acta Neuropathol 2017; 133: 245-261.
6. Maida CD, Norrito RL, Daidone M, Tuttolomondo A, Pinto A. Neuroinflammatory mechanisms in ischemic stroke: Focus on cardioembolic stroke, background, and therapeutic approaches. Int J Mol Sci 2020; 21: 6454-6487.
7. Liu R, Li Y, Zhang X, Tang K, Li J, Fang T, et al. Applications and mechanisms of taohong siwu decoction in the treatment of ischemic stroke. Pharmacogn Mag 2024; 20: 1071-1085.
8. Yang K, Zeng L, Yuan X, Wang S, Ge A, Xu H, et al. The mechanism of ferroptosis regulating oxidative stress in ischemic stroke and the regulation mechanism of natural pharmacological active components. Biomed Pharmacother 2022; 154: 113611-113633.
9. Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: An iron-dependent form of nonapoptotic cell death. Cell 2012; 149: 1060-1072.
10. Yang L, Guttman L, Dawson VL, Dawson TM. Parthanatos: Mechanisms, modulation, and therapeutic prospects in neurodegenerative disease and stroke. Biochem Pharmacol 2024; 228: 116174.
11. Yuan H, Pratte J, Giardina C. Ferroptosis and its potential as a therapeutic target. Biochem Pharmacol 2021; 186: 114486.
12. Su LJ, Zhang JH, Gomez H, Murugan R, Hong X, Xu D, et al. Reactive oxygen species‐induced lipid peroxidation in apoptosis, autophagy, and ferroptosis. Oxid Med Cell Longev 2019; 2019: 5080843-5080856.
13. Dodson M, Castro-Portuguez R, Zhang DD. NRF2 plays a critical role in mitigating lipid peroxidation and ferroptosis. Redox Biol 2019; 23: 101107-101114.
14. Yamada N, Karasawa T, Wakiya T, Sadatomo A, Ito H, Kamata R, et al. Iron overload as a risk factor for hepatic ischemia-reperfusion injury in liver transplantation: Potential role of ferroptosis. Am J Transplant 2020; 20: 1606-1618.
15. Shen Z, Liu T, Li Y, Lau J, Yang Z, Fan W, et al. Fenton-reaction-acceleratable magnetic nanoparticles for ferroptosis therapy of orthotopic brain tumors. ACS Nano 2018; 12: 11355-11365.
16. He YJ, Liu XY, Xing L, Wan X, Chang X, Jiang HL. Fenton reaction-independent ferroptosis therapy via glutathione and iron redox couple sequentially triggered lipid peroxide generator. Biomaterials 2020; 241: 119911.
17. Rochette L, Dogon G, Rigal E, Zeller M, Cottin Y, Vergely C. Lipid peroxidation and iron metabolism: Two corner stones in the homeostasis control of ferroptosis. Int J Mol Sci 2022; 24: 449-466.
18. Li X, Ma N, Xu J, Zhang Y, Yang P, Su X, et al. Targeting ferroptosis: Pathological mechanism and treatment of ischemia‐reperfusion injury. Oxid Med Cell Longev 2021; 2021: 1587922-158796.
19. Wang P, Cui Y, Ren Q, Yan B, Zhao Y, Yu P, et al. Mitochondrial ferritin attenuates cerebral ischaemia/reperfusion injury by inhibiting ferroptosis. Cell Death Dis 2021; 12: 447-463.
20. Guo H, Zhu L, Tang P, Chen D, Li Y, Li J, et al. Carthamin yellow improves cerebral ischemiareperfusion injury by attenuating inflammation and ferroptosis in rats. Int J Mol Med 2021; 47: 1-1.
21. Lochhead JJ, Ronaldson PT, Davis TP. The role of oxidative stress in blood–brain barrier disruption during ischemic stroke: Antioxidants in clinical trials. Biochem Pharmacol 2024; 2024: 116186.
22. Zhou Y, Liao J, Mei Z, Liu X, Ge J. Insight into crosstalk between ferroptosis and necroptosis: Novel therapeutics in ischemic stroke. Oxid Med Cell Longev 2021; 2021: 9991001.
23. Patt A, Horesh IR, Berger EM, Harken AH, Repine JE. Iron depletion or chelation reduces ischemia/reperfusion-induced edema in gerbil brains. J Pediatr Surg 1990; 25: 224-228.
24. Zhang Q, Jia M, Wang Y, Wang Q, Wu J. Cell death mechanisms in cerebral ischemia–reperfusion injury. Neurochem Res 2022; 47: 3525-3542.
25. Guan X, Li Z, Zhu S, Cheng M, Ju Y, Ren L, et al. Galangin attenuated cerebral ischemia-reperfusion injury by inhibition of ferroptosis through activating the SLC7A11/GPX4 axis in gerbils. Life Sci 2021; 264: 118660.
26.Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20: 84-91.
27. Kuge Y, Minematsu K, Yamaguchi T, Miyake Y. Nylon monofilament for intraluminal middle cerebral artery occlusion in rats. Stroke 1995; 26: 1655-1658.
28. Zhao HR, Wang M, Gao Y, Wu XM, Xiao H, Yang DS, et al. Vespakinin-M, a natural peptide from Vespa magnifica, promotes functional recovery in stroke mice. Commun Biol 2022; 5: 74-90.
29. Zeng YQ, Hao L, Chen Y, Liu SY, Fan Y, Zhao ZH, et al. Optimizing intra-arterial hypothermia scheme for acute ischemic stroke in an MCAO/R rat model. Sci Rep 2023; 13: 9566-9579.
30. Wang Q, Liu CJ, Chen MR, Zhao J, Wang DX, Gao PF, et al. Mastoparan M promotes functional recovery in stroke mice by activating autophagy and inhibiting ferroptosis. Biomed Pharmacother 2024; 174: 116560-116574.
31. Khanevski AN, Bjerkreim AT, Novotny V, Næss H, Thomassen L, Logallo N, et al. Recurrent ischemic stroke: incidence, predictors, and impact on mortality. Acta Neurol Scand 2019; 140: 3-8.
32. Shi ZS, Loh Y, Walker G, Duckwiler GR. Endovascular thrombectomy for acute ischemic stroke in failed intravenous tissue plasminogen activator versus non–intravenous tissue plasminogen activator patients: revascularization and outcomes stratified by the site of arterial occlusions. Stroke 2010; 41: 1185-1192.
33. Saver JL, Adeoye O. Intravenous thrombolysis before endovascular thrombectomy for acute ischemic stroke. JAMA 2021; 325: 229-231.
34. Maida CD, Norrito RL, Daidone M, Tuttolomondo A, Pinto A. Neuroinflammatory mechanisms in ischemic stroke: focus on cardioembolic stroke, background, and therapeutic approaches. Int J Mol Sci 2020; 21: 6454-6487.
35. Zhao Y, Zhang X, Chen X, Wei Y. Neuronal injuries in cerebral infarction and ischemic stroke: From mechanisms to treatment. Int J Mol Med 2022; 49: 15-24.
36. Andrabi SS, Parvez S, Tabassum H. Ischemic stroke and mitochondria: Mechanisms and targets. Protoplasma 2020; 257: 335-343.
37. Wang Z, Li Y, Ye Y, Zhu H, Zhang J, Wang H, et al. NLRP3 inflammasome deficiency attenuates cerebral ischemia-reperfusion injury by inhibiting ferroptosis. Brain Res Bullet 2023; 193: 37-46.
Iranian Journal of Basic Medical Sciences

Articles in Press, Accepted Manuscript
Available Online from 16 September 2025

Files

Share

How to cite

Statistics